




The UK's Premier Biotechnology  
and Investment Conference



Where **Great Minds**  
And **Smart Money**  
Meet **Under One Roof**

## Preliminary Programme

# BioTrinity 2009 Oxford

2 - 3 April 2009

The Quadrangle  
at Kassam Stadium

Organised by



[www.biotrinity.com](http://www.biotrinity.com)

# BioTrinity 2009 Sponsors and Partners

## Gold Sponsors:



## Silver Sponsors:



## Bronze Sponsors:



## Marketing & Communications Agent:



## Project Partners:



## Partnering by:



# BioTrinity 2009 - Oxford

Now in its 3rd year, OBN's **BioTrinity 2009** is the largest biotech & medtech **partnering conference** in the Oxford & South East biotech region, and is **unique** in showcasing this super-cluster's biotech companies, which lead the UK in attracting investment. BioTrinity 2009 tells the story of companies working successfully at all stages of development, from **concept to patient**.

Dear Colleague

I am delighted to present BioTrinity 2009 to the biotech community, with details of our excellent preliminary programme - for the **UK's premier biotech and investment conference**.

BioTrinity 2009 will maintain gold standard one-to-one partnering in private meeting rooms - an innovation you told us was very welcome. The social programme now features a pre-conference champagne reception and a Gala Dinner at Oxford Colleges as well as a golf tournament and investor-only dinner.

Crucial to successful partnering, we have so far seen 3-fold as many companies register for BioTrinity 2009, compared to the highly successful 2008 event. Buy in from Global Pharma includes licensing representation from **Roche, GSK, Novartis, BMS, Genzyme, Merck, Lilly, Takeda, Shire** and **Teva**.

Likewise, the UK's most exciting emerging biotechs will feature in the Company Showcase - including 2008's fundraisers and perhaps 2009's dealmakers? Vantia, Apitope, Circassia, Immunocore, and Adaptimmune among 35 showcase presentations.

At BioTrinity you can hear from your peers: the successful entrepreneurs from the companies acquired by pharma including Thiakis, Piramed and Arrow, and listen to some of Oxford's leading entrepreneurs in "Oxford's Great Minds". Can you afford to miss out on BioTrinity 2009?

Jon Rees, PhD - CEO, **OBN**



*"I found the feedback from presenting at the OBN meeting truly excellent. I not only had a lot of questions after the presentation but it generated press interest and many follow up meetings in the following days. This is testament to the quality of the attendees at the meeting"*

David Phillips, SVP, Sales and Marketing, **BioFocus DPI (Galapagos)**

*"...As a direct result of our focused partnering meetings we introduced proteros to potential clients at BioTrinity 2008 which we are pleased to report resulted in several new opportunities and one of which has developed into a substantial business relationship"*

Gordon J Woodrow, VP Business Development, **Proteros biostructures**

*"...I would like to congratulate you on an excellent meeting."*

Tim Haines, Partner, **Abingworth Management**

## Who will you meet at BioTrinity?

- ✦ Small, medium and large biotechnology companies
- ✦ Investors and entrepreneurs
- ✦ Mid & big pharma licensing executives
- ✦ Leading academics, researchers and their technology transfer commercial managers

## Why our delegates came last year\*

- ✦ Meet new contacts and renew contacts for business development
- ✦ Meet potential investors
- ✦ Keep up-to-date of new developments
- ✦ Raise and maintain company profile
- ✦ Seek out potential partners and deals
- ✦ Identify new collaborators, partners and suppliers

\*Gathered from what they told us in feedback

## Why attend?

74% delegates said their objectives were met  
73% delegates thought that the one-to-one partnering and informal networking were Excellent or Good

## BioTrinity 2008 statistics

500+ one-to-one partnering meetings  
2000 meeting requests  
400+ delegates  
270 companies  
12 countries represented

*"My first time at a UK partnering conference was BioTrinity 2008, and I did a deal with an NZ pharma as a **direct** result"*  
Allen Hakimi, MD, **Technomark Life Sciences**

# BioTrinity 2009 programme features

- ✧ Key deals presentations on the acquisitions of Thiakis, Piramed and Arrow by the senior management involved
- ✧ Panel discussions on Venture Capital, Alliances and Licensing
- ✧ Over 30 hand-picked company showcase presentations
- ✧ Independent workshops on finding funding

## Partnering

The gold standard online interactive one-to-one partnering system to enable companies to select suitable partners. This year we have the capacity to hold up to 1000 half-hour meetings over the 2 conference days in private rooms and booths.

## Networking with the best of the super-cluster

- ✧ Pre-conference Networking Reception on 1st April, at New College, Oxford
- ✧ Networking Reception with wine and canapés on 2nd April open to all delegates.
- ✧ Gala Dinner in the Dining Hall of St Hugh's College, Oxford on 2nd April
- ✧ Ample opportunities to network further during the breakfast, tea/coffee breaks, lunches and separate quiet zones for speakers and delegates
- ✧ Networking hub at the heart of the exhibition area



# BioTrinity 2009 Programme

## Day 1 - Thursday 2nd April

- 08.50 Welcome & Opening Remarks, Jon Rees, CEO, OBN
- 09.00 VIP Address: Mervyn Davies CBE, Minister for Trade and Investment (invited)
- 09.10 **Panel Discussion:**  
Thiakis, Piramed and Arrow - Returning half a billion dollars of value to investors: why VC's should invest in UK biotech companies.  
John Burt, CEO, Thiakis, David Knowles, ex CSO, Piramed, Ken Powell, ex CEO, Arrow Therapeutics
- 09.50 **Investor Panel Discussion:**  
Successful Fundraising in Tough Economic Climes (Oxford Suite)  
Atlas Venture, Novo Ventures, Oxford Capital Partners,  
Takeda Research Investment, Piper Jaffray, Genzyme Ventures
- 10.30 *Refreshments, Networking and Exhibition viewing*
- 11.00 **Plenary Talk: What Genzyme is looking for in the Oncology Pipeline,**  
Genzyme VP Oncology
- Companies Showcase - Sponsored by Shire Pharmaceuticals**
- 11.30 Shire Pharma - David Colpman, VP Introducing the Company Showcase
- 11.40 Adaptimmune, CSO
- 11.50 Novolytics, CSO
- 12.00 BioAlvo, CEO (invited company)
- 12.10 Immunocore, CEO
- 12.20 Cytos Group, CEO
- 12.30 *Lunch, networking and Exhibition Viewing*
- Companies Showcase presentations**
- 13.30 GlycoForm, CEO
- 13.40 Capsant Neurotechnologies, CSO
- 13.50 Particle Therapeutics, CEO
- 14.00 Vantia Therapeutics, CEO
- 14.10 Celleron Therapeutics, Founding Director
- 14.20 Circassia, CEO
- 14.30 Summit plc, tba
- 14.40 MorphoSys UK Ltd, MD
- 14.50 Oxford BioMedica, CEO
- 15.00 *Refreshments, Networking and Exhibition viewing*
- Companies Showcase presentations**
- 15.50 E-Therapeutics, CEO (Invited)
- 16.00 Aptuit, Manager
- 16.10 Cancer Research UK, Director
- 16.20 Gray Institute for Radiation Oncology & Biology (ROB), Director
- 16.30 Oxford Transplant Unit and Clinical Trial Service Unit (Director)
- 16.40 Diabetes Trials Unit, University of Oxford (Invited)
- 17.00 *Networking Reception at Kassam featuring the Diamond Stitch in Time Project* Sponsored by Shire Pharmaceuticals  
Followed by Gala dinner at St Hugh's College, Oxford (additional £69+VAT)

## Day 2 - Friday 3rd April

- 08.50 Review of our Year, OBN, CEO  
09.00 **Plenary Talk: EUSA Pharma and Philosophy, Building a leading transatlantic specialty Pharma**, CEO  
09.20 Key Developments: **Supporting the Growth of Biotech and Medtech Companies**, MEPC, Director  
09.30 **Plenary Talk: What Merck Wants**, Merck, Director  
09.45 **Plenary Talk: Perspective on Innovative Medicines Initiative (IMI)**, GSK, SVP

### Companies Showcase presentations

- 10:00 Glide Pharma, Director  
10.10 Apitope, CEO  
10:20 Hybrid Systems, CEO  
10.30 Refreshments, Networking and Exhibition viewing  
11.00 **Panel Discussion hosted by PharmaVentures**  
Successful deal making in tough economic climes.  
PharmaVentures, CEO (Chair); Roche, VP; Novartis Institutes of BioMedical Research; GSK, Director, Transactions; Cellzome, VP; Chroma Therapeutics, CEO

### Companies Showcase presentations

- 11.40 Domainex, CEO  
11.50 Inhibox, CEO  
12.00 Orthox, CEO  
12.10 Saltigo - Wolfgang Ebenbeck, Innovative fluorination methods and new fluorinated building blocks for life science R&D  
12.30 Lunch and Exhibition Viewing  
13.30 **Panel Discussion**  
Where Oxford's Great Minds Meet: How to be Successful in Biotech  
CMP Therapeutics, CEO; OSI Prosidion, EVP; Evotec, COO

### Companies Showcase presentations

- 14.00 Oxitec, CEO  
14.10 Epistem, CEO  
14.20 Oxford Gene Technology, CEO  
14.30 Eykona Technologies, CTO  
14.40 Organox, CEO (invited)  
14.50 Oxford Expression Technologies, CEO  
15.00 **The Final Word: Economic Forecast for Biotech in Europe, BioCentury**

## Partnering

One-to-one Partnering will take place in private partnering rooms on:

2 April 2009: 08.30 hrs - 17.00 hrs

3 April 2009: 08.30 hrs - 15.30 hrs

# Registration and Contact details

Register online at [www.biotrinity.com](http://www.biotrinity.com)

Hilary Boardman – Events Manager, Tel. +(0) 1865 594 644, [hilary.boardman@obn.org.uk](mailto:hilary.boardman@obn.org.uk)

## Companies already confirmed for BioTrinity 2009

GSK  
Roche  
Novartis Pharma AG (Switzerland)  
Genzyme  
Merck Sharp Dohme  
Bristol Myers-Squibb  
Eli Lilly  
Takeda Pharmaceuticals  
Shire Pharma  
Teva Pharmaceutical Industries  
(OSI) Prosidion  
EUSA Pharma  
Chroma Therapeutics  
Vantia Therapeutics  
Immunocore  
Debiopharm SA (Switzerland)  
Thiakis (now part of Wyeth)  
Syntaxin  
Domainex  
Cytos Group  
Hybrid Systems  
Eykona Technologies  
Oxford Gene Technology  
Oxford Expression Technologies  
GlycoForm  
Epistem  
Capsant Neurotechnologies  
Circassia  
Orthox  
Apitope  
Simbec Research  
De Facto Communications  
Regulatory Resources Group  
Inhibox  
UniTech Pharma (Sweden)  
Particle Therapeutics  
Glide Pharma  
Oxford BioMedica  
Cellzome  
AbD Serotec  
Solvias AG (Switzerland)  
Alchemy Healthcare  
Intertek  
PharmaTV  
Novolytics  
Cancer Research UK  
The Wellcome Trust  
Abingworth Management  
Atlas Venture  
Takeda Research Investment Inc  
Novo Ventures (Denmark)

Innovator Capital  
MP Healthcare Venture Management (USA)  
Oxford Capital Partners  
Niche Science & Technology  
OctoPlus N.V. (Netherlands)  
TNO Quality of Life (Netherlands)  
Epistem  
O2H  
Saltigo  
Summit plc  
BioConnection B.V. (Netherlands)  
Arrow Therapeutics (part of AZN)  
Life Scientific (Ireland)  
Aptuit  
CureVac (Germany)  
CMP Therapeutics  
Carbogen Amcis AG  
Evotec  
Eczacibasi Pharmaceuticals  
Covance Laboratories  
Cambridge Major Laboratories  
AdaptImmune  
Novasep Synthesis  
Ithaka Life Sciences  
Oxford Transplant Centre  
PharmaVentures  
Gray Institute for Radiation Oncology & Biology  
University of Manchester Intellectual Property Limited  
(UMIP)  
BioCentury  
Pharmaceutical Profiles  
Piper Jaffray  
Drug Discovery Today  
Physiomics plc  
BBSRC  
Synth-Isis  
Cognitive Drug Research  
Drug Intelligence  
Catalent Pharma Solutions  
Oxitec  
ThermoFisher Scientific  
Technomark Life Sciences  
MorphoSys UK  
SR One  
Excalibur  
H2O Venture Partners  
Genzyme Ventures  
Avlar Bioventures  
Oxford Technology Management  
Andy Richards

[www.biotrinity.com](http://www.biotrinity.com)